Skip to main content

Table 1 Patients information

From: Impact of treatment delay due to the pandemic of COVID-19 on the efficacy of immunotherapy in head and neck cancer patients

Patient ID Gender Age (years) Primary diagnosis Failure of disease Treatment lines Immunotherapy Combined chemotherapy Delay (months)
1 M 77 Mandible carcinoma Recurrence First line Toripalimab Nab-paclitaxel → GEM 3.27
2 M 73 Sino-nasal malignant tumors Metastasis First line Pembrolizumab Nab-paclitaxel 3.23
3 F 63 Oral cavity cancer Metastasis First line Pembrolizumab Nab-paclitaxel 3.50
4 M 51 Hypopharyngeal carcinoma Recurrence First line Toripalimab Nab-paclitaxel 3.23
5 M 56 Nasopharyngeal carcinoma Recurrence Second line Toripalimab S1 8.17
6 F 44 Nasopharyngeal carcinoma Metastasis First line Camrelizumab GEM 3.27
7 M 26 Parotid carcinoma Metastasis First line Camrelizumab Nab-paclitaxel 3.23
8 M 53 Oral cavity cancer Recurrence First line Camrelizumab GP → nab-paclitaxel 2.97
9 M 67 Oral cavity cancer Recurrence First line Toripalimab GEM 1.73
10 F 55 Oral cavity cancer Recurrence First line Pembrolizumab Nab-paclitaxel 4.57
11 M 50 Nasopharyngeal carcinoma Metastasis First line Camrelizumab Nab-paclitaxel → GEM 5.57
12 M 65 Nasopharyngeal carcinoma Metastasis First line Camrelizumab GEM 4.13
13 M 46 Nasopharyngeal carcinoma Recurrence First line Camrelizumab GP 3.50
14 M 30 Oral cavity cancer Recurrence First line Camrelizumab GP 4.13
15 M 58 Oral cavity cancer Metastasis First line Camrelizumab Nab-paclitaxel 3.13
16 M 69 Oral cavity cancer Recurrence First line Pembrolizumab Nab-paclitaxel 4.57
17 M 68 Oral cavity cancer Recurrence First line Camrelizumab Nab-paclitaxel 4.00
18 M 67 Hypopharyngeal carcinoma Metastasis Fourth line Toripalimab Vinorelbine 4.27
19 M 73 Nasopharyngeal carcinoma Recurrence First line Camrelizumab GEM 5.37
20 M 52 Oral cavity cancer Recurrence First line Camrelizumab GP → nab-paclitaxel 2.97
21 F 69 Oral cavity cancer Metastasis First line Toripalimab GEM 4.63
22 F 70 Oral cavity cancer Metastasis First line Camrelizumab GEM → nab-paclitaxel 4.37
23 M 58 Oral cavity cancer Recurrence First line Camrelizumab Nab-paclitaxel 3.13
24 M 49 Nasopharyngeal carcinoma Recurrence Fourth line Toripalimab Nab-paclitaxel 6.13
  1. M, male; F, female; GEM, gemcitabine; GP, gemcitabine plus cisplatin; S1, gimeracil and oteracil potassium capsules